General Information |
| Clinical trials phase |
Phase 2 |
| Start date (estimated) |
2025-06-30 |
| End date (estimated) |
2030-12-31 |
| Clinical feature |
| Label |
Parkinson's disease |
| Link |
http://purl.obolibrary.org/obo/DOID_14330 |
| Description |
A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT07028632 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT07028632 |
| Source weblink |
https://clinicaltrials.gov/study/NCT07028632 |
| Sponsors |
iRegene Therapeutics Co., Ltd.
|
Cells |
| Which differentiated cell type is used |
| Label |
dopaminergic neuron |
| Link |
http://purl.obolibrary.org/obo/CL_0000700 |
| Description |
A neuron that releases dopamine as a neurotransmitter. |
|
Recruitment |
| Recruitment Status |
Not yet recruiting |
| Estimated number of participants |
30 |
